Abstract: A Process for the Preparation of Pharmaceutical Composition of Apixaban. The present invention relates to a process for the preparation of pharmaceutical composition comprising Apixaban, the pharmaceutical composition resulting from this process and its use for the prophylaxis and/or treatment of a thromboembolic disorder.
| # | Name | Date |
|---|---|---|
| 1 | 201621001853-FORM 2-16-01-2017.pdf | 2017-01-16 |
| 2 | 201621001853-FORM 2(TITLE PAGE)-16-01-2017.pdf | 2017-01-16 |
| 3 | 201621001853-DESCIRIPTION(COMPLETE)-16-01-2017.pdf | 2017-01-16 |
| 4 | 201621001853-CORRESPONDENCE-16-01-2017.pdf | 2017-01-16 |
| 5 | 201621001853-CLAIMS-16-01-2017.pdf | 2017-01-16 |
| 6 | 201621001853-ABSTRACT-16-01-2017.pdf | 2017-01-16 |
| 7 | 201621001853-Other Patent Document-190116.pdf | 2018-08-11 |
| 8 | 201621001853-Form 5-190116.pdf | 2018-08-11 |
| 9 | 201621001853-Form 3-190116.pdf | 2018-08-11 |
| 10 | 201621001853-Form 2(Title Page)-190116.pdf | 2018-08-11 |
| 11 | 201621001853-Form 1-190116.pdf | 2018-08-11 |
| 12 | 201621001853-Form 18-100120.pdf | 2020-01-13 |
| 13 | 201621001853-Correspondence-100120.pdf | 2020-01-13 |
| 14 | 201621001853-FER.pdf | 2020-05-19 |
| 15 | 201621001853-ORIGINAL UR 6(1A) FORM 26-190321.pdf | 2021-10-18 |
| 16 | 201621001853-Marked Copy-061120.pdf | 2021-10-18 |
| 17 | 201621001853-Examination Report Reply Recieved-061120.pdf | 2021-10-18 |
| 18 | 201621001853-Claims-061120.pdf | 2021-10-18 |
| 19 | 201621001853-Annexure I-061120.pdf | 2021-10-18 |
| 20 | 201621001853-Abstract-061120.pdf | 2021-10-18 |
| 21 | 201621001853-ORIGINAL UR 6(1A) FORM 26-030822.pdf | 2022-08-04 |
| 22 | 201621001853-PatentCertificate17-08-2022.pdf | 2022-08-17 |
| 23 | 201621001853-IntimationOfGrant17-08-2022.pdf | 2022-08-17 |
| 24 | 403734-Correspondence (Renewal)-280922.pdf | 2022-10-03 |
| 25 | 403734-CORRESPONDENCE (RENEWAL)-221223.pdf | 2023-12-26 |
| 26 | 201621001853-FORM-27 [21-01-2025(online)].pdf | 2025-01-21 |
| 27 | 201621001853-FORM 4 [28-01-2025(online)].pdf | 2025-01-28 |
| 1 | searchstrategy201621001853E_15-05-2020.pdf |